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ABSTRACT 
Replication-deficient viral vectors are currently being used in gene transfer strategies to treat cancer cells. 
Unfortunately, viruses are limited in their ability to diffuse through tissue. This makes it virtually impossible 
to infect the majority of tumor cells in vivo and results in inadequate gene transfer. This problem can be ad-
dressed by allowing limited viral replication. Limited viral replication facilitates greater penetration of viri-
ons into tissue and can improve gene transfer. W e have developed a strategy of limited viral replication us-
ing AdRSVIaclys, a chemically modiiled El-deleted adenovirus, to codeliver an exogenous plasmid encoding 
the adenovirus E I region. This system allows one round of viral replication. W e examined the effect of this 
limited adenovirus replication in vitro and in vivo. In culture, codelivery of virus and pEI resulted in a large 
increase in infected cells when compared with control cells exposed to virus and pUCI9. In experiments on 
nude mice bearing H e L a ascites tumors, intraperitoneal injection of AdRSVlaclys/pEl resulted in a signifi-
cantly higher percentage of infected H e L a cells as compared with the P B S controls {p < 0.05) or the A d R S V -
laclys/pUCI9 controls {p < O.OI). These data demonstrate that the transcomplementation of replication-
deficient adenovirus with exogenous E l D N A leads to limited replication, and this controlled replication 
enhances gene transfer efficiency of adenovirus in vivo. 
OVERVIEW SUMMARY 
Replication-defective viral vectors are limited in their abil-
ity to diffuse through tissue. This poses a problem for treat-
ing tumors in vivo using gene transfer. This article demon-
strates that limited replication of adenovirus leads to greater 
gene transfer efficiency in vitro and in vivo without intro-
ducing additional safety concerns beyond traditional aden-
ovirus administration. This has implications for the im-
provement of current gene transfer methods for treating 
cancer. 
INTRODUCTION 
VIRAL VECTORS are among the most efficient vehicles for 
gene transfer in vitro and in vivo (Mulligan, 1993). For 
this reason, replication-deficient vural vectors have been used 
in various gene transfer approaches to treat cancer cells (Crys-
tal, 1995). Unfortunately, diis approach is limited in that it is 
nearly unpossible to infect the majority of tumor cells in vivo 
owing to physical constraints imposed by both the virus and tu-
mor. Tumors in vivo are usually present as solid masses or 
sheets many layers thick, as opposed to the easily infected 
monolayers in cell culture. Typical virions are large enough to 
prevent significant diffusion through these cell layers. In addi-
tion, in some in vivo animal models the amount of vims ad-
ministered is limited by the volume that can actually be phys-
ically injected. 
The limitations in vector delivery present a serious problem 
in targeting cancerous cells in vivo using gene transfer. Deliv-
ery of a cytotoxic or tumor-suppressing vims may temporarily 
slow down tumor growth, but is doomed ultimately to fail if 
some tumor cells are left unharmed. Even strategies with a "by-
stander effect" (such as the herpes simplex virus thymidine ki-
nase gene) require that a significant amount of mmor cells be 
infected, and most successful animal models of thymidine ki-
nase delivery have involved the administration of retroviral pro-
ducer cell lines to ensure that this is the case (Culver et al, 
1992; Takamiya et al, 1992; Barba et al, 1994). 
It may be possible to circumvent viral delivery problems with 
controlled replication of a viral vector in vivo (Goldsmith, 
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FIG. 1. Schematic diagram of limited replication in vivo. O n 
the left, conventional techniques result in gene transfer only 
near the surface of tissue. O n the right, limited replication al-
lows virus diffusion to deeper areas in the tissue. Viral repli-
cation is occurring in dark cells. 
1994). This could allow greater penetration of the vims beyond 
the first several cell layers (see Fig. 1). Limited replication 
would also increase the effective local viral titer. For controlled 
replication to occur, the genes necessary for viral replication 
must be codelivered with the viral vector. However, these genes 
must not be engineered into the viral genome or the result would 
be a fully replication-competent vims. W e have developed a 
model of controlled in vivo replication using adenovirus. Ade-
novims is relatively chemically stable and can be manipulated 
by adding polylysine without completely destroying infectious 
activity (Wagner et al, 1992; Cristiano et al, 1993; Fisher and 
Wilson, 1994). This allows exogenous D N A to bind to the mod-
ified adenovims by electrostatic interactions and "piggyback" 
its way into infected cells. By using this method to codeliver a 
plasmid encoding the adenovims El region, standard El-
deleted adenovirus can enter a round of replication. W e will re-
fer to this method as limited replication, because barring re-
combination events, all of the progeny of this process will be 
replication deficient, eliminating virus replication after one 
round. Adenovirus also has other favorable properties for use 
in this system. Adenovirus can be produced at high titers and 
infect a broad range of dividing and nondividing cells 
(Kozarsky and Wilson, 1993). In addition, adenovims has a 
lytic life cycle, which lyses the cell after vims replication is 
complete and thus may expose more tumor surface area for fur-
ther gene transfer. 
Other viral vectors all have one or more deficiencies for use 
in such a system. Retrovims integrates into the host genome 
and will continually produce vims for the life of the cell (as-
suming the transgene is not lethal). Both of these properties are 
safety concerns (Varmus, 1988). Retrovims is also surtounded 
by a relatively unstable lipid bilayer that is difficult to modify 
chemically without completely abolishing biologic activity 
(Rosenberg et al, 1997). Herpes simplex vims has a similar bi-
layer and presents possible toxicity concerns (Glorioso et al, 
1997). Adeno-associated vims (AAV) cannot replicate without 
adenovims (Fisher et al, 1997), which defeats the purpose of 
using A A V in the first place. Therefore, adenovims appears to 
be the ideal choice for this system. 
Here w e demonstrate that transcomplementation of replica-
tion-deficient adenovuiis with exogenous El D N A leads to lim-
ited viral replication. W e have constructed a simple system in 
which adenovirus plasmid D N A complexes can be used to 
achieve this effect in vitro. Finally, w e have extended this study 
to demonstrate enhanced gene delivery in a relevant in vivo 
model. This addresses a major problem in current approaches 
to cancer gene therapy. 
MATERIALS AND METHODS 
In vitro limited replication of adenovirus using 
liposomes 
Construction of AdRSVIacZ has been described (Davidson 
et al, 1994). The plasmid pEl, which contains the E l A and 
ElB regions of adenovims (nucleotides 1-5778), was a gift 
from E. White (White and Cipriani, 1989). This plasmid, as 
well as all plasmids described hereafter, was purified by cen-
trifugation through a CsCl-ethidium bromide gradient (Sam-
brook etal, 1989). HeLa cells (human cervical carcinoma) were 
maintained in Dulbecco's modified Eagle's medium ( D M E M ) 
containing 1 0 % fetal bovine s e m m (FBS) and 1 % P/S (peni-
cillin [100 intemational units/ml] and streptomycin [100 
/Ug/ml]). S K O V 3 (human ovarian carcinoma) cells were main-
tained in McCoy's 5A medium containing 1 0 % F B S and 1 % 
P/S. 
Cells were seeded in six-well dishes and allowed to reach 
8 0 % confluence. Lipofectamine (GIBCO-BRL, Gaithersburg, 
M D ) was used to lipofect either 1 pg of p U C 1 9 or 1 pg of pEl 
into each well. Lipofection procedures were done as recom-
mended by the manufacturer. After 24 hr at 37°C, the medium 
was replaced with 2 ml of fresh medium ( 2 % FBS, 1 % P/S) 
containing 1 X 10^ AdRSVIacZ viral particles. Each well was 
fed with 2 ml of medium ( 2 % FBS, 1 % P/S) on day 3 and 
stained on day 6 or 8 with 5-bromo-4-cbloro-3-indolyl-j8-D-
galactosidase (X-Gal). Before staining, cells were fixed in 0.5% 
glutaraldehyde for 10 min and washed twice with phosphate-
buffered saline (PBS)-1 m M MgCl2. Stained cells were exam-
ined by light microscopy and photographed. 
Preparation of adenovirus/polylysine complex 
Polylysine was cross-linked to replication-deficient, recom-
binant adenovirus using a slightly modified version of a pro-
cedure described elsewhere (Fisher and Wilson, 1994). To 
maleimide-activate the vims, AdRSVIacZ was prepared and 
concentrated on a CsCl gradient. After centrifugation, this virus 
was immediately desalted on a 15-ml Sephadex G-50 column 
equilibrated with PBS, p H 7.0. The viral particle concentration 
was determined by absorbance at 260 nm, on the assumption 
that one absorbance unit equals 1 X 10'^ viral particles/ml. The 
titered virus was diluted to approximately 5 X 10'^ particles/ml 
and sulfosuccinimidyl-4-(W-maleimidomethyl)cyclohexane-1 -
carboxylate (Pierce, Rockford, IL), was added to a final con-
centration of 25 m M . This reaction was rocked gentiy at room 
temperature for 7.5 min, then stopped by adding a one-tendi 
volume of 1 M Tris, p H 7.0. 
While maleimide-activating the adenovims, a thiol group 
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was added onto the amino terminus of poly-L-lysine (54 kDa; 
Sigma, St. Louis, M O ) using 2-iminothiolane essentially as de-
scribed (Fisher and Wilson, 1994). The 2-iminothiolane was re-
moved on a 15-ml Sephadex G-25 column equilibrated with 
100 m M Tris (pH 7.1 at 4°C), 100 m M NaCl, and 2 m M EDTA. 
The first fraction that contained virus as determined by ab-
sorbance at 220 nm was saved for further use. 
The purified, thiolated polylysine was diluted to a volume 
equal to that of the maleimide-activated adenovims mixture us-
ing 100 m M Tris (pH 7.1 at 4°C), 100 m M NaCl, and 2 m M 
EDTA. Then the maleimide-activated virus and modified 
polylysine were mixed and rocked gentiy at 4°C for 90 min. 
The polylysine is cross-linked to the virus at this step. Unre-
acted maleimide groups were blocked by adding a one-tenth 
volume of 1 M 2-mercaptoethylamine and incubating for 20 
min at room temperature. To remove unincorporated polylysine 
and concentrate the virus, the polylysine-modified virus was 
then centrifuged on a CsCl gradient. The vims was desalted on 
a 15-ml Sephadex G-50 column. Storage was in 50 m M Tris 
(pH 7.1), 50 m M NaCl, 1 m M EDTA, and 5 0 % glycerol at 
-80°C. This modified virus will be referred to as AdRSVIa-
clys. 
Successful cross-linking was verified by a gel mobility shift 
assay. In a total volume of 100 pi of PBS, 200 pg of the plas-
mid pK7GFP (a gift from I. Macara; Casey et al, 1996) was 
incubated with varying amounts of modified or unmodified 
vims for 30 min at room temperature. These samples were re-
solved by gel electrophoresis on a 1.5% agarose gel. 
Transfection of exogenous DNA in vitro using the 
adenovirus/polylysine complex 
W e determined that the amount of cross-linked adenovims 
necessary to infect more than 8 0 % of HeLa cells was approx-
imately 1 X 10^ viral particles/cell. Therefore, this titer was 
used for the following infections. AdRSVIacZ or AdRSVIaclys 
was incubated with or without pK7GFP in a total volume of 
100 pi of PBS for 20-30 min at room temperature. HeLa cells 
at 1 X 10' cells/well in 12-well dishes were washed once with 
PBS and 0.5 ml of D M E M (2% FBS, 1% P/S) was added to 
each well. Vims/DNA mixtures were added to their respective 
wells and the cells were incubated at 37°C ovemight. The next 
day, the medium was replaced with 1 ml of D M E M (10% FBS, 
1% P/S) per well. Each experiment was performed in duplicate. 
One set was trypsinized, fixed, and stained with X-Gal to mon-
itor infection efficiency. The other set was trypsinized, washed 
once with PBS, and visualized for green fluorescent protein 
(GFP) using a fluorescence microscope to monitor adenovims-
mediated transfection efficiency. The percentage of infected or 
transfected cells was determined with a hemacytometer and data 
represent the mean ± standard deviation of two experiments. 
In vitro limited replication of adenovirus using the 
adenovirus/polylysine complex 
AdRSVIacZ or AdRSVIaclys was incubated with either 2 ^g 
of pUC19 or 2 jU.g of pEl in a total volume of 200 pi of PBS 
for 20-30 min at room temperamre. HeLa or S K N S H cells at 
1.5 X lO'/well in six-well dishes were washed once with PBS 
and 1 ml of D M E M (2% FBS, 1% P/S) was added to each well. 
Vims/DNA mixtiires were added to their respective wells and 
the cells were placed at 37°C ovemight. The next day, medium 
was replaced with 2 ml of D M E M (2% FBS, 1% P/S). Cells 
were fed on days 3 and 6 with 2 ml of D M E M (2% FBS, 1% 
P/S). No medium was removed during this time. On day 8 
postinfection, the cells were fixed and stained with X-Gal to 
monitor limited replication of the adenovirus. Staining was ei-
ther done in the dish and subsequentiy photographed or done 
in suspension and the percentage of cells infected was deter-
mined with a hemacytometer. 
In vivo limited replication of adenovirus 
Nude mice (CD-I nu/nu; Charles River, Wilmington, MA) 
were injected intraperitoneally with 1X10-' HeLa cells. Four 
days later the mice were injected with a vims/DNA mixture in 
100 /xl of PBS, using a Hamilton syringe. Each injection con-
tained 7 X 10' particles of AdRSVIaclys with either 2 pg of 
pUC19 or 2 pg of pEl. Two mice were injected with PBS only. 
These injections were repeated every other day for a total of 
four injections. 
Eight days after the final injection (to allow time for limited 
replication) mice were sacrificed. The peritoneal cavity was 
washed twice with 1.5 ml of PBS and the resulting cell sus-
pension was removed and saved. These samples were cen-
trifuged at 350 X g in a microcentrifuge for 2 min, washed once 
with PBS, and recentrifuged. The resulting pellets of HeLa and 
blood cells were resuspended in 1 ml of D M E M (10% FBS, 
1% P/S) each and placed in six-well dishes in a total volume 
of 2 ml of medium. These dishes were cultured at 37°C for 2 
days in order to allow most of the blood cells to die or lyse. 
The dishes were then washed six times with PBS and the re-
maining HeLa cells were fixed and stained with X-Gal for 48 
hr at 37°C. Cells were examined by light microscopy and pho-
tographed. The percentage of infected cells was determined for 
each sample. Groups were compared using a one-sided Student 
t test. 
Detection of the adenovirus hexon protein 
Twenty-four hours after infection with the chemically mod-
ified AdRSVIaclys and 2 pg of either pUC12 or pEl, HeLa 
cells were harvested and attached to microscope slides. Im-
munohistochemistry using a fluorescein isothiocyanate (FITC)-
conjugated anti-hexon IgG (Cbemicon, Temecula, C A ) was 
done using the protocol recommended by the supplier. Mi-
croscopy was performed with a Zeiss fluorescence microscope. 
RESULTS 
Independent codelivery of the pEl plasmid and 
adenovirus in vitro 
To test whether exogenous El plasmid DNA could 
transcomplement replication-deficient adenovims in vitro, an 
independent plasmid lipofection was followed by AdRSVIacZ 
infection of HeLa or S K 0 V 3 cells. A low titer of AdRSVIacZ 
was used for these experiments in order to make viral replica-
tion easdy detectable. Over the course of the next 6 to 8 days, 
cells initially transfected with pEl showed a substantially 
FIG. 2. Lipofection of plasmid D N A followed by adenoviral infection. Cells were lipofected with 1 pg of pUC19 (left) or pEl 
D N A (right), then infected with AdRSVIacZ. X-Gal staining is shown at 6 and 8 days. (A) HeLa cells at 6 days; (B) HeLa cells 
at 8 days; (C) S K 0 V 3 cells at 6 days; (D) S K 0 V 3 cells at 8 days. 
greater proportion of infected cells than those initially trans-
fected with the pUC19 control (Fig. 2A). The staining pattem 
on El-transfected cells was present in clusters, indicating areas 
where limited replication and subsequent cell lysis occurred. 
There was a greater amplification of the adenovims in the HeLa 
cells. This may be due to either greater amplification of vims 
in HeLa cells or greater susceptibility to adenovirus infection 
of HeLa cells. This verifies our hypothesis that codelivery of 
pEl will support viral replication. 
Although this shows that the codelivery concept is feasible. 
FIG. 3. Gel mobility shift of polylysine-modified adenovims. 
AdRSVIaclys, AdRSVIacZ, or no vims was incubated with 200 
pg of plasmid D N A . Attachment of D N A to AdRSVIaclys re-
sults in a large complex with neutralized charge that does not 
m n into the gel. Lane a, 2.5 X 10' particles of AdRSVIaclys 
plus D N A ; lane b, 5 X 10' particles of AdRSVIaclys plus D N A ; 
lane c, 1 X 10'° particles of AdRSVIaclys plus D N A ; lane d, 
2.5 X 10'° particles of AdRSBIaclys plus D N A ; lane e, 2.5 X 
lO'Oparticlesof AdRSVIacZ plus D N A ; lane f, 2.5 X 10'° par-
ticles of AdRSVIacZ (no D N A ) ; land g, D N A only. 
the methodology used for these pilot experiments is not prac-
tical for general in vivo use. Liposomes have been shown to de-
liver genes in vivo, but the efficiency varies dramatically de-
pending on cell type/animal model and would probably need to 
be extensively optimized for most scenarios (Gao and Huang, 
1995). Thus, other methods were explored for the codelivery 
ofpEl. 
Codelivery of plasmid DNA with adenovirus/polylysine 
complex 
Polylysine-modified adenovims has been shown to complex 
with and transfect plasmid D N A (Wagner et al, 1992; Cris-
tiano et al, 1993; Fisher and WOson, 1994). W e planned to use 
such a vims to codeliver the pEl plasmid. Our method of cross-
linking polylysine to AdRSVIacZ was based on the procedure 
of Fisher and Wilson. This previously reported method essen-
tially modified the entirety of the adenoviral capsid. The mod-
ified vims, AdRSVIaclys, would bind to plasmid D N A (Fig. 3). 
W e aimed next to demonstrate that AdRSVIaclys could nans-
feet plasmid D N A without the assistance of tertiary substrates 
(such as a polylysine-modified cellular ligand). This would sim-
plify infection procedures for future in vivo experiments. Ap-
proximately 1 5 % of HeLa cells infected with AdRSVIaclys also 
introduced the pK7GFP plasmid when examined by fluores-
cence microscopy (Fig. 4). Because fluorescence microscopy 
to detect G F P is not terribly sensitive, we expect that the ac-
tual percentage of nansfected cells is higher. In con&ast, cells 
exposed to plasmid alone or plasmid widi AdRSVIacZ exhib-
ited no detectable G F P expression. Thus, the polylysine at-
tached to adenovirus allows codelivery of plasmid D N A . 
O n the basis of these experiments, we predicted dial deliv-
ery of the pEl plasmid complexed with AdRSVIaclys would 
result in significantiy enhanced gene transfer owing to a round 






AdRSVIacZ -- . . + + + + . . . . 
AdRSVIaclys + ++.,. 
plC7GFP + + - - + + - - + + . 
FIG. 4. Transfection of plasmid DNA with AdRSVIaclys. AdRSVIaclys, AdRSVIacZ, or no virus was incubated widi pK7GFP 
before infection of H e L a cells. (A) AdRSVlaclys-infected cells under light; (B) AdRSVIaclys-infected cells using fluorescence 
microscopy; (C) the infection and transfection efficiencies of various combinations of vims and D N A on H e L a cells. (A and B ) 
magnification: X200. Addition of plasmid D N A caused a slight decrease in infectivity. This is most likely due to reduced cell 
membrane binding because of the negatively charged D N A . 
A 
3 2 % ± 6 
m 
c 
2 1 % ± 1 8 l % + l f 
FIG. 5. Limited replication of AdRSVIaclys in H e L a cells. (A) AdRSVIacZ premcubated with p U C 1 9 ; (B) AdRSVIacZ prem-
cuba'ted with pEl; (C) AdRSVIaclys preincubated with p U C 1 9 ; (D) AdRSVIaclys preincubated with pEl. Original magnifica-
tion X200. Percent infected ± sSD is indicated for (A)-(D). 
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FIG. 6. Limited replication of AdRSVIaclys in SKNSH cells. 
The experiment described in Fig. 5 was extended to SKNSH 
cells. 
of viral replication. Transfection of only 15% of infected cells 
translates into a great deal of additional vims when one con-
siders that the typical adenovims life cycle results in l(y viral 
progeny (Shenk, 1996). When AdRSVIaclys and pEl were used 
to infect HeLa cells, a large increase in infected cells was ob-
served by X-Gal staining when compared with the control 
AdRSVlaclys/pUC19 sample (Fig. 5). Once again, clusters of 
blue cells indicated areas of viral replication. As expected, in-
fection of HeLa cells with AdRSVIacZ resulted in the same 
amount of gene transfer regardless of preincubation with pEl 
or pUC19. This experiment generated analogous results when 
repeated with SKNSH (human neuroblastoma) cells, indicating 
that this effect is not specific to HeLa cells (Fig. 6). 
It is possible that the replication observed in AdRSVIaclys/pEl 
infected/transfected cells was due to recombination of the repli-
cation-defective AdRSVIaclys genome with the transfected pEl 
plasmid to generate replication-competent helper viras. This pre-
sents a potential safety concem for future in vivo applications of 
this method. To address this concem, the AdRSVlaclys/pEl in-
fection was repeated on HeLa cells. These infections were har-
vested at 4 days postinfection, freeze-thawed, and the supematant 
of this lysate was used to infect a new monolayer of HeLa cells 
in a 35-mm dish. These cells were monitored over the next 14 
days for the appearance of cytopathic effect (CPE). As a posi-
tive control, HeLa cells were incubated with various dilutions of 
sub360, which is both the original adenovims strain used to gen-
erate AdRSVIacZ (Davidson et al, 1994) and the predicted re-
combination product of pEl and AdRSVIaclys. Dilutions ranged 
from lO'* viral particles (the amount of virions generated from 
one viral life cycle) to 10* viral particles/well. All dilutions of 
sub360 produced CPE within die 2-week time period, as evi-
denced by completely detached, swelled, or lysed cells. Mono-
layers from HeLa cells cultured with the AdRSVlaclys/pEl in-
fection extract were intact after 14 days and showed no signs of 
CPE (data not shown). This strongly suggests that the limited vi-
ral replication observed widi AdRSVlaclys/pEl infections is due 
to transcomplementation, not recombmation. This also suggests 
that helper vuiis is not a significant contributing factor to any of 
the resuhs presented in this study. 
Enhanced gene transfer in vivo using limited 
replication of AdRSVIaclys 
To demonstrate the ability of limited replication to improve 
transduction efficiency in vivo, AdRSVIaclys complexes were 
injected into mice bearing HeLa ascites mmors. After a series 
of four injections, the viras was allowed 8 days to replicate, in-
fect more cells, and express ;3-galactosidase. At the time of sac-
rifice, there was no apparent toxicity to mice injected with virus. 
X-Gal staining revealed a low percentage of infected HeLa cells 
in mice injected with PBS or AdRSVlaclys/pUC19 (data sum-
marized in Table 1). A higher infection percentage was appar-
ent in HeLa cells isolated from mice injected with AdRSVla-
clys/pEl when compared with the PBS group (p < 0.05) or the 
AdRSVIaclys/pUC19 group (p < 0.01). Transduction effi-
ciency reached close to 9 0 % in one of the mice (Fig. 7C). In 
vivolvirvLS. replication was confirmed. El transfected cells in-
fected with the lacZ recombinant adenovims, but not the 
pUC19-transfected cells infected with the same recombinant 
viras, produced the adenovirus late hexon protein (Fig. 8). 
These data provide evidence that limited replication results in 
a significantiy higher proportion of tumor cells mfected in vivo. 
DISCUSSION 
Viral vectors are extremely attractive as gene transfer vehi-
cles owing to their evolved mechanisms for introducing genetic 
material into cells. This has led to extensive efforts in adapting 
virases for the delivery of therapeutic genes (Miller, 1992). In 
some cases (such as cystic fibrosis), delivery of the therapeu-
tic gene theoretically needs to take place only in a small pro-
Table 1. Efhciency of Gene Transfer 
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FIG. 7. Examples of limited replication of AdRSVIaclys in vivo. Ascites were injected, harvested, and stained as described in 
Materials and Methods. (A) P B S (mouse 5); (B) AdRSVIaclys with pUC19 (mouse 6); (C) AdRSVIaclys with pEl (mouse 9). 
Original magnification: X200. 
portion of affected cells in order to produce significant bene-
fits. However, in other cases, infection of the majority of the 
target cells may be necessary. For example, the proliferative 
nature of cancer dictates that it is necessary to infect the ma-
jority, if not all, transformed cells in order to achieve true clin-
ical benefit from gene transfer. This problem is exacerbated by 
the extreme difficulty of transducing the majority of targeted 
cells in vivo, since viruses can diffuse only for limited distances 
in solid tissues. 
Limited viral replication represents a strategy for improving 
the efficiency of transducing target cells in vivo. The feasibil-
ity of limited replication has been demonstrated here and by 
others in vitro with several cell lines, using a model system con-
sisting of an El-deleted adenoviral vector that could introduce 
exogenous El sequences (on a plasmid), permitting replication 
(Goldsmith et al, 1994). Because diese D N A sequences were 
separate from the adenovirus genome and thus were not incor-
porated into adenoviral progeny, all of the resultant virions were 
replication defective, ending replication after one round. Min-
imal helper virus was produced, which indicates that this 
method may be as safe as naditional adenovirus administration. 
Adenoviral thymidine kinase-mediated regression of subcuta-
neous tumors in nude mice arising from cells transfected with 
'El kin vitro was greater than regression of mmors arising from 
parental cells (Dion et al, 1996). W e have also extended these 
results to show that Iknited replication of adenovirus leads to 
enhanced gene transfer in vivo. The potential of the El plasmid 
with the adenovirus vector to form a replication-competent ade-
noviras could be further minimized by using an El plasmid 
with no sequences that are shared with the adenovims vector. 
The model system presented in this study is intended only 
to demonsfrate the principle of limited replication and can ob-
viously be improved. Safety concems regarding the transform-
ing potential of integrated pEl plasmid sequences can be alle-
viated by engineering a suicide gene such as the herpes simplex 
virus thymidine kinase gene into the plasmid. Cells that con-
tain the pEl plasmid can then be purged from the body, using 
gancyclovir after the course of treatment. Furthermore, aden-
ovirus cross-linking procedures that result in greater transfec-
tion and infection activity have been reported, and would likely 
lead to better in vivo results (Cristiano et al, 1993). Ideally, 
though, chemical modification of the adenovims capsid would 
not take place because it invariably decreases infectability. A 
plausible altemative would have the El sequences packaged in-
side the adenovims capsid (but not in the genome), which would 
A 
B 
FIG. 8. In vivo expression of the adenovnus hexon protein in 
HeLa cells. Immunohistochemistry showing expression of the 
adenoviras hexon protein in HeLa cells infected with AdRSVIa-
clys conjugated with either pUC19 (A) or pEl (B). Original 
magnification: X200. 
1216 HAN ET AL. 
result in 100% of infected cells undergoing a round of replica-
tion, provided the cells are permissive. Cuixent technology does 
not allow us to do this. Another possible scenario would be to 
place the El sequences in the adenovims genome, but under 
tumor-specific promoters. This could be difficult since it is 
likely that leaky El expression would occur owing to viral en-
hancers present throughout the adenovirus genome (Shenk, 
1996). 
Limited replication could be especially useful for cancers 
arising in cavities where adenoviras is easily administered. T w o 
examples of this are bladder and ovarian cancer. Bladder can-
cers are superficial tumors that arise focally, or diffusely, ini-
tially penetrating only a few cell layers of the bladder lumenal 
epithelium. Ovarian cancer initially spreads in the peritoneal 
cavity. In both of these cases, it may be possible to infect all 
transformed cells using limited replication of adenoviras. This 
would also be a probable improvement on curtent gene trans-
fer methods in solid tumor masses, although it is still unlikely 
that all the cells of a large tumor mass can be transduced. In 
summary, we have shown that limited replication of adenovims 
is safe and results in enhanced gene transfer both in vitro and 
in vivo. This addresses the problem of inadequate gene trans-
fer in cancer gene therapy and may eventually lead to potential 
clinical benefits in the future. 
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